SCHEMBL13544971

SCHEMBL13544971

CCCc1ccc(C(=O)Nc2c[nH]nc2-c2nc3ccccc3[nH]2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ PKM P14618 1/20 0.52
▸ KLF5 Q13887 1/20 0.52
▸ MAPT P10636 4/20 0.51
▸ FOXO1 Q12778 1/20 0.48
▸ HPSE Q9Y251 1/20 0.48
▸ TP53 P04637 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ HDAC1 Q13547 3/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ AURKA O14965 1/20 0.47
▸ CDK1 P06493 1/20 0.47
▸ CCNB1 P14635 1/20 0.47
▸ CDK2 P24941 1/20 0.47
▸ AURKB Q96GD4 1/20 0.47
▸ TRPV1 Q8NER1 1/20 0.47
▸ MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12582491 0.90 HPSE (0.48) NPC1RAB9APKMKLF5MAPT
SCHEMBL12252494 0.90 HPSE (0.48) NPC1RAB9APKMKLF5MAPT
SCHEMBL8305763 0.88 HPSE (0.50) NPC1RAB9APKMKLF5MAPT
SCHEMBL1646052 0.86 CDK1 (0.61) NPC1RAB9APKMMAPTHPSE
SCHEMBL13544970 0.82 NPC1 (0.66) NPC1RAB9APKMKLF5MAPT
SCHEMBL8305732 0.80 HPSE (0.50) NPC1RAB9APKMMAPTHPSE
SCHEMBL8306072 0.80 NPC1 (0.66) NPC1RAB9APKMKLF5MAPT
SCHEMBL1646700 0.79 AURKA (0.59) NPC1RAB9APKMHPSETP53
SCHEMBL8299886 0.79 CDK1 (0.47) NPC1RAB9APKMMAPTFOXO1
SCHEMBL12252623 0.78 CDK1 (0.47) NPC1RAB9APKMMAPTHPSE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004232-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (UK) 2010-01-07 — — US disclosed
US-20100004232-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (UK) 2010-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004232-A1 Pharmaceutical Compounds ERBB3, ABL1, RET NPC1 3367/4885RAB9A 1208/4885PKM 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback